Introduction Proton beam therapy is an established primary treatment for patients with non-metastasized uveal melanoma. Adjuvant local interventions, like intravitreal injections or surgery, were shown to improve long-term eye preservation; however, their impact on the patient’s quality of life (QOL) remains unknown. Methods In a post-radiotherapeutic follow-up, we prospectively collected data on QOL, visual acuity, and interventional adjuvant procedures. QOL was measured with QOL-C30 and QLQ-OPT30 questionnaires at baseline, and at three and twelve months after proton therapy. Patients were grouped by the type of adjuvant treatment. Impact on QOL was analyzed by comparing changes in mean score values and visual acuity for different interventional subgroups, with generalized linear mixed models and Wilcoxon signed-rank tests. Results We received 108 (100%) and 95 (88.0%) questionnaires at three and twelve months post-therapy, respectively. Adjuvant interventions included: observation (n=61, 56.5%), intravitreal injections (n=17, 15.7%), and an intraocular surgical procedure (n=30, 27.8%). In the latter group, several QOL items significantly declined after the 3 month adjuvant interval, but they partially recovered at the 12-month follow-up. In all adjuvant-intervention groups, global QOL scores returned to baseline levels at 12 months. Conclusion Post-treatment adjuvant interventions had no long-lasting effects on QOL in patients with uveal melanoma.


中文翻译：

---

眼部辅助干预对质子束治疗后葡萄膜黑色素瘤患者生活质量的影响

引言 质子束治疗是非转移性葡萄膜黑色素瘤患者的主要治疗方法。辅助局部干预，如玻璃体内注射或手术，被证明可以改善长期的眼睛保护；然而，它们对患者生活质量 (QOL) 的影响仍然未知。方法 在放射治疗后的随访中，我们前瞻性地收集了有关 QOL、视力和介入辅助手术的数据。在基线以及质子治疗后三个月和十二个月时，使用 QOL-C30 和 QLQ-OPT30 问卷测量 QOL。患者按辅助治疗的类型分组。通过使用广义线性混合模型和 Wilcoxon 符号秩检验比较不同干预亚组的平均分值和视力的变化，分析对 QOL 的影响。结果 我们在治疗后三个月和十二个月分别收到了 108 (100%) 和 95 (88.0%) 份问卷。辅助干预包括：观察 (n=61, 56.5%)、玻璃体内注射 (n=17, 15.7%) 和眼内手术 (n=30, 27.8%)。在后一组中，几个 QOL 项目在 3 个月的辅助间隔后显着下降，但在 12 个月的随访中部分恢复。在所有辅助干预组中，总体 QOL 评分在 12 个月时恢复到基线水平。结论 治疗后辅助干预对葡萄膜黑色素瘤患者的生活质量没有长期影响。和眼内手术 (n=30, 27.8%)。在后一组中，几个 QOL 项目在 3 个月的辅助间隔后显着下降，但在 12 个月的随访中部分恢复。在所有辅助干预组中，总体 QOL 评分在 12 个月时恢复到基线水平。结论 治疗后辅助干预对葡萄膜黑色素瘤患者的生活质量没有长期影响。和眼内手术 (n=30, 27.8%)。在后一组中，几个 QOL 项目在 3 个月的辅助间隔后显着下降，但在 12 个月的随访中部分恢复。在所有辅助干预组中，总体 QOL 评分在 12 个月时恢复到基线水平。结论 治疗后辅助干预对葡萄膜黑色素瘤患者的生活质量没有长期影响。